Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05309460 · ClinicalTrials.gov registry record · Phase 4

Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial

A Phase 4 study of Hypertension in Pregnancy and Postpartum Preeclampsia, sponsored by Nebraska Methodist Health System.

Recruiting
Registry status
Phase 4
Development phase
600
Enrollment target
1
Study location

NCT05309460 is a Phase 4 study of Hypertension in Pregnancy and Postpartum Preeclampsia that is actively recruiting participants, run by Nebraska Methodist Health System. The registered enrollment target is 600 participants, above the 402-participant average among 13 other Hypertension in Pregnancy trials with a reported enrollment target (49% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05309460, a Phase 4 study of Hypertension in Pregnancy and Postpartum Preeclampsia, is actively recruiting participants, sponsored by Nebraska Methodist Health System.

RECRUITING
Registry status
Phase 4
Development phase
600 participants
Enrollment target
1
Study location

Study Summary

Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.

Interventions

  • DRUG Labetalol Oral Tablet
  • DRUG NIFEdipine ER

Study Locations (1)

Nebraska

  • Nebraska Methodist Women's Hospital - Omaha

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2022-06-20
Est. Completion 2024-12-01
Phase Phase 4

Sponsor

Nebraska Methodist Health System

5 total trials

What the Registry Record Tells You About NCT05309460

The ClinicalTrials.gov registry entry for NCT05309460 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 402-participant average among 13 other Hypertension in Pregnancy trials with a reported enrollment target (49% higher). The listed sponsor is Nebraska Methodist Health System, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hypertension in Pregnancy appearing as the primary indexed condition, and to 2 interventions - of which Labetalol Oral Tablet is the first listed.

NCT05309460 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.

Frequently Asked Questions

What is clinical trial NCT05309460 about?

NCT05309460 is a clinical study titled "Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial". Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.

What is the current status of trial NCT05309460?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 2022-06-20. Estimated completion is 2024-12-01.

What conditions does trial NCT05309460 study?

This clinical trial studies the following conditions: Hypertension in Pregnancy, Postpartum Preeclampsia.

What interventions are being tested in trial NCT05309460?

The interventions under investigation include: Labetalol Oral Tablet (DRUG), NIFEdipine ER (DRUG).

Who is sponsoring clinical trial NCT05309460?

This trial is sponsored by Nebraska Methodist Health System, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05309460 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension in Pregnancy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.